Close Menu

The Wall Street Journal has a commentary piece from Sidney Taurel, chairman and CEO of Eli Lilly and Company, on a recent flare-up over a drug candidate in clinical trials. The heart-attack drug, prasugrel, was in two trials that were halted pending review of a few cases of adverse effects. Taurel says the media coverage that followed this not only got the story wrong, but resulted in cutting Lilly's market cap by "about $6 billion."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.